MISSED OUT ON THE LATEST CLINICAL GUIDELINE ANNOUNCEMENTS?

No problem, we’ve got you covered! Here’s a list to all guidelines and FDA approvals that were published last month. 


CLINICAL GUIDELINES

AAP

ACR/AAHKS

ADA

AGA

ASCO

ASHECO/ASNC/SCCT/SCMR

ASMBS

ASTRO

ENDO

WHO


EXCLUSIVE SOCIETY GUIDELINES AND MANY MORE!

Search, bookmark, add notes and create your personal clinical guideline library with your digital copy or one of our society and specialty subscription bundles.   


FDA APPROVALS

JUNE 1, 2022       BEOVU
Treatment of diabetic macular edema (DME)­

­JUNE 6, 2022       RIABNI
In combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies­

JUNE 6, 2022     PRIORIX
For active immunization for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older­

­JUNE 7, 2022      DUPIEXENT
For children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable­

­JUNE 13, 2022     OLUMIANT
Treatment for adults with severe alopecia areata (AA)­

JUNE 13, 2022     AMVUTTRA
Treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults­

­JUNE 13, 2022     CELLCEPT
Prophylaxis of organ rejection in pediatric recipients of allogenic heart and allogeneic liver transplants aged 3 months and older in combination with other immunosuppressants­

­JUNE 17, 2022     SKYRIZI
Treatment of moderately to severely active Crohn’s disease in adults­

­JUNE 17, 2022      IMCIVREE
For chronic weight management in adults and pediatric patients age 6 and older with obesity due to Bardet-Biedl Syndrome (BBS)­

­JUNE 22, 2022      VAXNEUVANCE
Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older­

JUNE 27, 2022      QSYMIA
For chronic weight management in pediatric patients 12 years and older who defined as having a body mass index (BMI) of 95th percentile or greater when standardized for age and sex­

­JUNE 27, 2022      BREYANZI
For the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL)­


Copyright © 2022 Guideline Central, All rights reserved.